Investigational drug · Phase 3
Pasritamig
Also called: JNJ-78278343
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
9
Any phase or sponsor naming "Pasritamig"
First trial start
2025
Sep 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pasritamig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Metastatic Castration-resistant Prostatic Neoplasms
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms, Castration-Resistant
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Pasritamig" as an intervention, largest first.
- A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07164443 · 1,203 participants (planned) · Start Sep 2, 2025 · Primary completion Aug 18, 2028
Drug: Pasritamig; Best Supportive Care (BSC) and 1 more · For: Metastatic Castration-resistant Prostatic Neoplasms
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 176 sites in all
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07225946 · 800 participants (planned) · Start Dec 19, 2025 · Primary completion Nov 19, 2027
Drug: Pasritamig; Docetaxel and 1 more · For: Prostatic Neoplasms, Castration-Resistant
Sites: Chandler, Arizona; Little Rock, Arkansas; Springdale, Arkansas · 165 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06095089 · 355 participants (planned) · Start Nov 1, 2023 · Primary completion Jun 21, 2027
Drug: JNJ-78278343; JNJ-87189401 and 3 more · For: Prostatic Neoplasms
Sites: Aurora, Colorado; Atlanta, Georgia; Minneapolis, Minnesota · 22 sites in all
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05818683 · 300 participants (planned) · Start Apr 26, 2023 · Primary completion Aug 31, 2027
Drug: Pasritamig; Cetrelimab and 8 more · For: Metastatic Castration-resistant Prostate Neoplasms; Metastatic Hormone-sensitive Prostate Cancer
Sites: Sarasota, Florida; Grand Rapids, Michigan; Brooklyn, Mississippi · 15 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07082920 · 140 participants (planned) · Start Jul 7, 2025 · Primary completion Nov 30, 2027
Drug: JNJ-78278343; JNJ-95298177 and 1 more · For: Prostatic Neoplasms
Sites: Sarasota, Florida; New York, New York; Cleveland, Ohio · 6 sites in all
GI Innovation, Inc.Industry
NCT07871435 · 107 participants (planned) · Start Oct 12, 2026 · Primary completion Mar 31, 2029
Drug: GI-102; Pasritamig · For: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sites: New York, New York; Seoul, South Korea · 6 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07319871 · 40 participants (planned) · Start Jan 14, 2026 · Primary completion Jan 7, 2027
Drug: Pasritamig; JNJ-86974680 · For: Prostatic Neoplasms
Sites: Sarasota, Florida; New York, New York; Cleveland, Ohio · 5 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT07860255 · 18 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2028
Drug: Pasritamig · For: Prostate Cancer
Sites: Seattle, Washington
Coherus Oncology, Inc.Industry
NCT07945821 · 12 participants (planned) · Start Nov 2026 · Primary completion Aug 2028
Drug: Tagmokitug; Pasritamig · For: Solid Tumor
Sites: Seattle, Washington
Newest research
PubMed records naming it or its code names, newest first.
- Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025.
Ismaili N · Front Endocrinol (Lausanne) 2026
- Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Stein MN, Vinceneux A, Robbrecht D, et al. · J Clin Oncol 2025
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.